Alpha Cognition (ACOG) investor relations material

Commercial performance and market opportunity

• ZUNVEYL, the first oral Alzheimer's treatment approved in 15 years, achieved over 16,000 prescriptions in its first four quarters and generated $3.5M in Q1 2026 revenue, reflecting a 23% quarterly increase in pharmacy orders.

• The total addressable market is estimated at $2B, with a strategic focus on the long-term care (LTC) segment, which represents 36% of the market and offers favorable access conditions.

• Early payor coverage includes 45% potential Medicare coverage, with over 25 million Medicare lives and 90% of prescriptions currently approved.

• The commercialization strategy targets 5,000 nursing homes and 3,000 healthcare providers, supported by a dedicated sales and reimbursement team.

• Sufficient cash reserves are in place to fund operations through expected operating breakeven in 2027.

Product differentiation and clinical profile

• ZUNVEYL is a novel galantamine prodrug designed to minimize side effects and improve long-term outcomes by optimizing dose and bioavailability.

• The dual mechanism of action enhances acetylcholine levels and modulates nicotinic receptor sensitivity, addressing both cognitive and behavioral symptoms of Alzheimer's disease.

• Clinical studies support significant and sustained improvements in cognitive and functional performance, with no significant impact on sleep or incidence of insomnia.

• ZUNVEYL’s design avoids gastrointestinal and central cholinergic side effects common in existing therapies, offering a compelling alternative for patients and caregivers dissatisfied with legacy treatments.

Clinical development and upcoming milestones

• Multiple country approvals for ZUNVEYL are anticipated in 2026, including in China.

• Key clinical studies include RESOLVE (Phase 4, AD patients with behaviors), CONVERGE (retrospective LTC analysis), and BEACON (real-world effectiveness in LTC), with topline data expected in Q3 2026.

• Additional milestones include completion of sublingual PK and pivotal trials, IND submissions, and TBI toxicity study results through 2027.